Pharmatest forges new California connections
Press Release | Pharmatest Services Ltd
MARCH 21, 2017
Turku, Finland: – Oncology and skeletal disease specialist CRO Pharmatest Services Ltd (Pharmatest) is boosting its North American business by joining two influential and wide-reaching organizations in California, Biocom and Science Exchange.
Biocom is one of the most influential life science advocacy and networking organizations in North America, while Science Exchange is the leading online marketplace for scientific research. By joining Biocom and Science Exchange Pharmatest expects to find new customers and further accelerate US sales of its CRO preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases.
Joining Biocom and Science Exchange is the next step in increasing investments in US marketing for Pharmatest that started with the opening of its first US sales office in Boston in early 2013 and its second sales office in San Diego in July 2016.
“Being a member of Biocom and a Science Exchange Verified Provider will allow potential customers to find Pharmatest more directly and help showcase our strengths as a reliable partner with high quality services,” commented Pharmatest CEO Jussi Halleen.
“Our increased investments in US marketing in recent years have shown their value, as we have increased our US sales by more than 50% per year after 2014. I am convinced that joining Biocom and Science Exchange will help us substantially in reaching our goal to achieve at least similar growth figures for our US sales also in the coming years,” Mr. Halleen added.
Pharmatest Services Ltd (Pharmatest) is a contract research organization (CRO) specializing in clinically predictive preclinical efficacy services in the therapeutic areas of oncology and skeletal diseases.
Pharmatest helps establish proof-of-efficacy of cancer drug candidates with cell culture assays, organotypic 3D models, orthotopic animal models, and disseminated cancer models. Its models of skeletal diseases include bone cell culture assays and animal models of osteoporosis and osteoarthritis that can also be used for bone safety testing.
Headquartered in Turku, Finland, Pharmatest’s preclinical research unit offers modern research facilities including fully equipped laboratories and barrier-type animal facilities.
The CRO has supported more than 100 clients from pharmaceutical and biotechnology organizations worldwide in research to develop new therapeutics against cancer and skeletal diseases. It has also assisted many nutraceutical companies in the development of new phytopharmaceutical products.
Pharmatest has developed a proven ability to reduce costs and notably increase the speed of drug development by processing outsourced preclinical efficacy testing with maximum efficiency and providing clients with access to latest translational tools for lead validation and proof-of-concept studies in oncology and skeletal diseases.
Jussi Halleen; CEO, Pharmatest Services Ltd.
Tel.: + 358 50 380 9551